Simulations Plus (SLP) Reports Prelim. Q4 Rev. of $24.1M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Simulations Plus (SLP) Reports Prelim. Q4 Rev. of $24.1M

Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2017

October 3, 2017 8:30 AM EDT

Company Reports Record Fourth-Quarter and Full-Year Revenues

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today released preliminary revenues for its fiscal fourth quarter (4QFY17) and full fiscal year 2017 (FY2017) ended August 31, 2017.

Mr. John R. Kneisel, chief financial officer of Simulations Plus, stated: This quarter represents the first quarter where were reporting preliminary consolidated annual and fourth quarter revenues that include... More